Isbufylline

TargetMol
Product Code: TAR-T9817
Supplier: TargetMol
CodeSizePrice
TAR-T9817-1mg1mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9817-1mL1 mL * 10 mM (in DMSO)£380.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9817-5mg5mg£422.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9817-10mg10mg£589.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9817-25mg25mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9817-50mg50mg£1,179.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9817-100mg100mg£1,564.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9817-500mg500mg£3,058.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Isbufylline can exert significant anti-inflammatory actions, in addition to its bronchodilator activity.
CAS:
90162-60-0
Formula:
C11H16N4O2
Molecular Weight:
236.275
Purity:
0.98
SMILES:
CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12

References

Celardo A, et al. Simultaneous determination of isbufylline and its major metabolites in rabbit blood and urine by reversed-phase high-performance liquid chromatography. J Chromatogr. 1991 Aug 23;568(2):407-18. Manzini S, et al. Isbufylline, a new xanthine derivative, inhibits airway hyperresponsiveness and airway inflammation in guinea pigs. Eur J Pharmacol. 1993 Nov 16;249(3):251-7. Meini S, et al. Isbufylline, a xanthine derivative, inhibits bronchoconstrictor responses produced by stimulation of capsaicin-sensitive sensory nerves in guinea-pig: 'In vitro' and 'in vivo' evidence. Pulm Pharmacol. 1993 Dec;6(4):279-86.